CONNECT WITH US
HealthTech

HealthTech

HLTH 2026: GLP-1 costs remain a challenge. A new CVS study aims to identify the right price

Fierce Healthcare logo

Published on

Add as a preferred source on Google
HLTH 2026: GLP-1 costs remain a challenge. A new CVS study aims to identify the right price

LAS VEGAS — Cost and access to GLP-1s remains a challenge, but the benefits of these drugs aren't in doubt.

A new study from CVS Health aims to quantify at what price a GLP-1 drug has generated enough savings elsewhere through improved clinical outcomes. The healthcare giant used anonymized claims data from Aetna members in fully insured plans and found savings from reduced hospital and medical spending, as well as improved health outcomes.

But those benefits weren't enough to offset the increased pharmaceutical spending at the current price point, the study found.

The study tracked a mix of members who took GLP-1s from 2023 to 2025, so some patients had three years of follow-up care and management.

Amy Compton-Phillips, M.D., chief medical officer at CVS, told Fierce Healthcare that part of the challenge in this equation is that these drugs gained steam as a treatment for obesity at a high price. And while those costs have come down, the reductions haven't yet been enough to offset the expenditures.

Another challenge for employers in particular — where GLP-1 coverage has been most in flux — is turnover, she said. While GLP-1s do drive significant improvements, an employer may not reap the benefit of the reduced cost if an employee moves to a different company before those are realized, even though they paid for the medication initially.

The study sought to identify a price point where those savings would be felt, and landed at $350 per month over a three-year period. Achieving that, Compton-Phillips said, would likely lure employers into embracing broader GLP-1 coverage.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.